In Fabry disease, progressive glycolipid accumulation leads to damage in kidney and other organs. This study was designed to determine the prevalence rate of Fabry disease in Japanese dialysis patients.
All dialysis patients agreeing to Japan Fabry disease screening study (J-FAST) with informed consent were selected except for Fabry disease. The screening was performed by a method of measuring plasma and/or leukocytes lysosomal α-galactosidase A protein level and α-galactosidase A activity. If positive, genetic analysis was carried out upon patient’s agreement.
J-FAST dealt with 8547 patients (male 5408, female 3139). At the tertiary examination, 26 out of 8547 patients were found to be positive. Six out of 26 patients could not accept genetic analysis because of death. Remaining 20 patients agreed with genetic analysis; then 2 patients (male 2, female 0) had a variation of the α-Gal gene and 11 patients showed E66Q variations. Therefore, the frequency of Fabry disease in J-FAST was 0.04 % (2/5408) in males and 0 % (0/3139) in females, and then 0.02 % (2/8547) in all patients. The presumptive clinical diagnoses of end-stage kidney disease (ESKD) were 10 chronic glomerulonephritis, 7 diabetic nephropathy, 3 unknown etiology, 3 nephrosclerosis, 1 gouty nephropathy, 1 autosomal dominant polycystic kidney disease and 1 renal tuberculosis among 26 tertiary positive patients. Two male Fabry patients were initially diagnosed as nephrosclerosis and chronic glomerulonephritis.
The prevalence rate of Fabry disease in J-FAST was 0.02 %. Moreover, Fabry disease could not be ruled out as the clinical diagnosis of ESKD.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Kint JA. Fabry’s disease: alpha-galactosidase deficiency. Science. 1970;167(3922):1268–9.
De Francesco PN, Mucci JM, Ceci R, et al. Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab. 2013;109:93–9.
Grünfeld JP, Lidove O, Joly D, Barbey F. Renal disease in Fabry patients. J Inherit Metab Dis. 2001;24(Suppl 2):71–4.
Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transpl. 2009;24:2102–11.
Waldek S, Germain DP, Wanner C, Warnock DG. Enzyme replacement therapy for Fabry’s disease. Lancet. 2010;375(9725):1523.
Kodama C, Nakao M, Takenaka T. Is Fabry disease a rare disease? On screening of Fabry disease in chronic dialysis male patients and its clinical feature. The report of idiopathic cardiomyopathy The Ministry of Health and Welfare, 1995; 41–4.
Utsumi K, Kase R, Takata T, et al. Fabry disease in patients receiving maintenance dialysis. Clin Exp Nephrol. 2000;4:49–51.
Spada M, Pagliardini S. Screening for Fabry disease in end-stage nephropathies. J Inherit Metab Dis. 2002;25(Suppl 1):113.
Linthorst GE, Hollak CE, Korevaar JC, et al. Alpha-Galactosidase a deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transpl. 2003;18:1581–4.
Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64:801–7.
Kotanko P, Kramar R, Devrnja D, et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol. 2004;15:1323–9.
Tanaka M, Ohashi T, Kobayashi M, et al. Identification of Fabry’s disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol. 2005;64:281–7.
Bekri S, Enica A, Ghafari T, et al. Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron Clin Pract. 2005;101:c33–8.
Ichinose M, Nakayama M, Ohashi T, et al. Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol. 2005;9:228–32.
Merta M, Reiterova J, Ledvinova J, et al. A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transpl. 2007;22:179–86.
Porsch DB, Nunes AC, Milani V, et al. Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report. Ren Fail. 2008;30:825–30.
Fujii H, Kono K, Goto S, et al. Prevalence and cardiovascular features of Japanese hemodialysis patients with Fabry disease. Am J Nephrol. 2009;30:527–35.
Terryn W, Poppe B, Wuyts B, et al. Two-tier approach for the detection of alpha-galactosidase a deficiency in a predominantly female haemodialysis population. Nephrol Dial Transpl. 2008;23:294–300.
Gaspar P, Herrera J, Rodrigues D, et al. Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Med Genet. 2010;11:19.
Nishino T, Obata Y, Furusu A, et al. Identification of a novel mutation and prevalence study for Fabry disease in Japanese dialysis patients. Ren Fail. 2012;34:566–70.
Doi K, Noiri E, Ishizu T, et al. High-throughput screening identified disease-causing mutants and functional variants of α-galactosidase A gene in Japanese male hemodialysis patients. J Hum Genet. 2012;57:575–9.
Kikumoto Y, Sugiyama H, Morinaga H, et al. The frequency of Fabry disease with the E66Q variant in the α-galactosidase A gene in Japanese dialysis patients: a case report and a literature review. Clin Nephrol. 2012;78:224–9.
Maruyama H, Takata T, Tsubata Y, et al. Screening of male dialysis patients for Fabry disease by plasma globotriaosylsphingosine. Clin J Am Soc Nephrol. 2013;8:629–36.
Nakai S, Iseki K, Itami N, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2009). Ther Apher Dial. 2012;16:11–53.
Kitagawa T, Suzuki K, Ishige N, et al. Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes. Pediatr Nepherol. 2008;23(9):1461–71.
Desnick RJ, Allen KY, Desnick SJ, et al. Fabry’s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine and leukocytes. J Lab Clin Med. 1973;81:157–71.
Mayes JS, Scheerer JB, Sifers RN, et al. Differential assay for lysosomal α-galactosidase in human tissues and its application to Fabry’s disease. Clin Chim Acta. 1981;112:247–51.
Kobayashi M, Ohashi T, Fukuda T, et al. No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene. Mol Genet Metab. 2012;107:711–5.
Lee BH, Heo SH, Kim GH, et al. Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. J Hum Genet. 2010;55:512–7.
Inoue T, Hattori K, Ihara K, et al. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet. 2013;58:548–52.
Tuttolomondo A, Pecoraro R, Simonetta I, et al. Anderson-Fabry disease: a multiorgan disease. Curr Pharm Des. 2013;19(33):5974–96.
Brady RO, Tallman JF, Johnson WG, et al. Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry’s disease. N Engl J Med. 1973;289:9–14.
Desnick RJ, Dean KJ, Grabowski G, et al. Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase a isozymes. Proc Natl Acad Sci USA. 1979;76:5326–30.
Weidemann F, Niemann M, Störk S, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274(4):331–41.
Smid BE, Rombach SM, Aerts JM, et al. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis. 2011;6:69.
Desnick RJ. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase a orphan products and one FDA approval. Expert Opin Biol Ther. 2004;4:1167–76.
Demontis R. Diagnosis of Fabry disease: usefulness of the clinical investigation. Rev Med Intern. 2010;31(Suppl 2):S229–32.
We would like to our sincere thank for their efforts of conducting J-FAST in various areas of JAPAN to the members of local committee listed below. In addition, we also express of our thanks to all the doctors and staff members of cooperative clinics for performing J-FAST. Dr Ichiei Narita, Niigata University Graduate School of Medical and Dental Sciences. Dr Kazutaka Kukita, Sapporo Hokuyu Hospital. Dr Yoshio Taguma, Sendai Shakaihoken Hospital. Dr Kaoru Tabei, Saitama Medical Center, Jichi Medical University. Dr Shigeko Hara, Toranomon Hospital. Dr Tadao Akizawa, Showa University School of Medicine. Dr Seiichi Matsuo, Nagoya University School of Medicine. Dr Yukio Yuzawa, Fujita Health University School of Medicine. Dr Yoshiharu Tsubakihara, Osaka General Medical Center. Dr Hirofumi Makino, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. Dr Hitoshi Sugiyama, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. Dr Noriaki Yorioka, Hiroshima Kidney Organization. Dr Takahito Nasu, Tokuyama Central Hospital. Dr Kumio Tomita, Graduate School of Faculty of Life Science, Kumamoto University. Dr Kunitoshi Iseki, University Hospital of the Ryukyu.
Conflict of interest
The authors have declared that no conflict of interest exists.
Sources of support
Kidney Foundation, Japan.
About this article
Cite this article
Saito, O., Kusano, E., Akimoto, T. et al. Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST). Clin Exp Nephrol 20, 284–293 (2016). https://doi.org/10.1007/s10157-015-1146-7
- Α-galactosidase activity
- Fabry disease
- Dialysis patient
- X-linked recessive inheritance
- E66Q variation